Evofem Biosciences entered into a securities purchase agreement on April 8, 2025, to issue $2.3 million in convertible notes and warrants, with a partial closing resulting in $1.15 million raised; Aditxt must provide an additional $1.5 million by April 7, 2025, or the merger may be terminated.